



**Supplementary Fig. 1.** Dose-dependent inhibition of PCSK9 binding to the EGF-AB domain of the LDLR by CB\_36. Inhibition of PCSK9 binding to the LDLR was assayed using a Circulex PCSK-LDLR *in vitro* binding assay kit (MBL International, Woburn, MA, USA) as described under “Materials and Methods.” The relative binding intensity in the presence of the vehicle (at a concentration of 0) was set as 100%. The data represent the mean  $\pm$  SD of triplicate measurements. PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein receptor.